Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...
SAN FRANCISCO, CA, USA and SUZHOU, China I March 14, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...
(Reuters) -The U.S. Food and Drug Administration has revoked the emergency use authorization for four COVID-19 antibody-based ...
At a time when global coordination against health threats is critical, recent policy shifts in the U.S. have created a ...
Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...
ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.
MedPage Today on MSN3d
Brain Edema, Imaging Abnormalities Reported for Alzheimer's DrugTreatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...
US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
Pharmaceutical Technology on MSN3d
Vaccinex plans Nasdaq exit as Alzheimer market pressure growsVaccinex went public in 2018, raising around $40m to advance its pipeline of neurodegenerative disease therapies. The initial ...
Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory reviews in ...
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback